Trial Profile
A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs HTERT DNA vaccine Invectys (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Invectys
- 21 May 2021 Results evaluating safety and immunogenicity presented at the 112th Annual Meeting of the American Association for Cancer Research
- 28 Sep 2019 Results assesing 3 escalating doses of INVAC-1 in patients with solid tumors were presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
- 26 Sep 2019 Results assessing multiple dosing of INVAC-1 as a single agent in patients with relapsed or refractory solid tumors presenting progressive disease published in the Clinical Cancer Research